Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

IMNM

Immunome Inc

Jan 16 • 04:00PM ET

22.41

-0.44 -1.93 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA NVAX SRPT NTLA CRSP PFE GILD BNTX BEAM

| Held by: VTI IWM XBI VXF IWO SCHA VTWO VHT IWC CANC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.96	Insider Own	8.27%	Shs Outstand	110.33M	Perf Week	6.36%
Market Cap	2.47B	Forward P/E	-	EPS next Y	-2.59	Insider Trans	-3.33%	Shs Float	101.22M	Perf Month	-4.56%
Enterprise Value	2.20B	PEG	-	EPS next Q	-0.59	Inst Own	80.20%	Short Float	17.32%	Perf Quarter	35.90%
Income	-222.74M	P/S	255.43	EPS this Y	55.23%	Inst Trans	9.64%	Short Ratio	8.69	Perf Half Y	111.81%
Sales	9.68M	P/B	7.79	EPS next Y	-15.58%	ROA	-80.08%	Short Interest	17.53M	Perf YTD	4.33%
Book/sh	2.88	P/C	9.07	EPS next 5Y	22.53%	ROE	-93.04%	52W High	25.30 -11.42%	Perf Year	121.66%
Cash/sh	2.47	P/FCF	-	EPS past 3/5Y	-32.63% -38.15%	ROIC	-83.13%	52W Low	5.15 335.14%	Perf 3Y	463.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	71.34%	Volatility	7.37% 6.31%	Perf 5Y	93.19%
Dividend TTM	-	EV/Sales	227.68	EPS Y/Y TTM	63.58%	Oper. Margin	-2137.10%	ATR (14)	1.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.90	Sales Y/Y TTM	-4.44%	Profit Margin	-2301.30%	RSI (14)	59.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.90	EPS Q/Q	16.50%	SMA20	6.22%	Beta	2.32	Target Price	34.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	14.88%	Rel Volume	0.97	Prev Close	22.85
Employees	118	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	79.97%	Avg Volume	2.02M	Price	22.41
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.94% -100.00%	Trades		Volume	1,951,354	Change	-1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Initiated	Truist	Buy	$36
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Show Previous Ratings

Jan-15-26 11:35AM	Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? (Insider Monkey) +10.07%
Jan-08-26 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" (Insider Monkey)
Jan-06-26 08:00AM	Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:05PM	Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer (CNBC TV) -5.33%
08:16PM	Loading…
Dec-16-25 08:16PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire) -15.76%
07:26AM	Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win (Clinical Trials Arena)
Dec-15-25 06:03PM	Why Immunome Stock Surged Today (Motley Fool) +15.69%
04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
04:34PM	Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA (Investor's Business Daily)
04:01PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
12:53PM	Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week (TheStreet)
07:00AM	Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-14-25 04:00PM	Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Nov-25-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Nov-06-25 04:05PM	Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.35%
Oct-31-25 11:51AM	Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference (Business Wire)
Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Loading…
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGALL CLAY B	President and CEO	Dec 30 '25	Buy	21.15	4,729	100,018	665,254	Dec 30 06:47 PM
Barchas Isaac	Director	Dec 22 '25	Sale	21.74	383,200	8,330,080	2,031,181	Dec 23 04:41 PM
SIEGALL CLAY B	President and CEO	Dec 19 '25	Buy	20.48	7,278	149,053	860,525	Dec 22 07:38 AM
Tsai Philip	Chief Technical Officer	Dec 19 '25	Buy	20.49	10,000	204,900	43,300	Dec 22 07:32 AM
SIEGALL CLAY B	President and CEO	Dec 18 '25	Buy	21.50	46,511	999,986	853,247	Dec 18 05:03 PM
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM
Higgins Jack	Chief Scientific Officer	Mar 27 '25	Option Exercise	1.35	5,200	7,020	18,729	Mar 28 05:54 PM
BIENAIME JEAN JACQUES	Director	Mar 25 '25	Buy	7.78	7,800	60,684	31,415	Mar 26 04:05 PM
SIEGALL CLAY B	President and CEO	Mar 26 '25	Buy	7.29	137,100	999,459	806,736	Mar 26 04:03 PM
BIENAIME JEAN JACQUES	Director	Mar 24 '25	Buy	8.21	7,000	57,470	23,615	Mar 25 05:18 PM
Tsai Philip	Chief Technology Officer	Mar 24 '25	Buy	8.42	12,300	103,566	33,300	Mar 25 05:15 PM
SIEGALL CLAY B	President and CEO	Jan 31 '25	Buy	7.75	150,000	1,162,500	669,636	Feb 03 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNM

Immunome Inc

Upgrade your FINVIZ experience